艾昆纬-《中东与非洲医药商业季刊》第三十六版（英）

© 2025. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries. Thirty-Sixth EditionMiddle East & AfricaPharmaceutical Business InsightsReport Release Date: Jun 2025Analytical Timeframe: MAT Mar 20251DisclaimerIQVIA is not an “authorised person” for the purposes of the Financial Services and Markets Act 2000 (“FSMA”) and does not provide investment advice or carry on any other regulated activity under Part II of the FSMA 2000 (Regulated Activities) Order 2001The forecasts, projections, and related information contained herein are made and provided subject to the assumptions, methodologies, caveats, and variables described in this report and are based on third party sources and data reasonably believed to be reliable. No warranty is made as to the completeness or accuracy of such third party sources or dataThis report, in part or in whole, is not intended to constitute investment advice, and is not a recommendation to purchase or not purchase, an endorsement of, or an opinion as to the value of, any security or any investment instrument of any entityAs with any attempt to estimate future events, the forecasts, projections, conclusions, and other information included herein are subject to certain risks and uncertainties, and are not to be considered guarantees of any particular outcomeThis report shall not be published, nor shall any public references to IQVIA be made regarding these services or this report, without IQVIA’ prior written approval. When so provided, this report and the information herein must always be provided and used in its entirety, including this complete Disclaimer pageThis report is subject to the IQVIA General Terms and Conditions.2+ Newsletter report summary+ Regional summary and analysis+ Spotlight on new offering+ AppendixAgenda3Business insights snapshot MAT Q1 2025: Many countries have witnessed high growth in 2025•Retail channel dominates the MEA Region with 67.3% ($24.76 B) share in value sales with 14.9% PPG and volume share of 81.6% (7.2 B Units) with 2.75% PPG•Growth of Hospital channel has increased in terms of PPG 20.1% in value and decreased by -1.36% PPG in volume•MNCs lead with 57.73% share in total value sales with 12.86% PPG•Local companies have grown at 21.96% PPG in value and 3.94% PPG in volume•Sanofi, Novartis and GSK continue to be the top MNC corporations in MEA contributing 23.3% to total MNC Sales•Amongst the top 10 corporation, Eli Lilly is the fastest growing corporation growing at 59.2% PPG•Alimentary Tract, Metabolism is the top TA holding 20.4% of value share with the highest contribution share from KSA at 37.5%1. PPG: Previous Period Growth: MAT Q1 2025 vs. MAT Q1 2024 growth2. CAGR: Compound Annual Growth Rate for the period MAT Q1 2021 to MAT Q1 2025;Source: IQVIA Audited Data, MAT Q1 2025, includes IQVIA private, LPO, Institutional data where available; Analysis based on Algeria, Egypt, Fr. West Africa, Jordan,